These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1152 related articles for article (PubMed ID: 23199957)

  • 1. Human papillomavirus vaccine introduction--the first five years.
    Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
    Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
    Poljak M
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of human papillomavirus immunization in the developing world.
    Kane MA; Serrano B; de Sanjosé S; Wittet S
    Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects and challenges in the introduction of human papillomavirus vaccines in the extended Middle East and North Africa region.
    Jumaan AO; Ghanem S; Taher J; Braikat M; Al Awaidy S; Dbaibo GS
    Vaccine; 2013 Dec; 31 Suppl 6():G58-64. PubMed ID: 24331821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
    Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
    Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Australian experience with the human papillomavirus vaccine.
    Garland SM
    Clin Ther; 2014 Jan; 36(1):17-23. PubMed ID: 24417782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
    Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
    Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-licensure monitoring of HPV vaccine in the United States.
    Markowitz LE; Hariri S; Unger ER; Saraiya M; Datta SD; Dunne EF
    Vaccine; 2010 Jul; 28(30):4731-7. PubMed ID: 20188681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.
    Koulova A; Tsui J; Irwin K; Van Damme P; Biellik R; Aguado MT
    Vaccine; 2008 Dec; 26(51):6529-41. PubMed ID: 18805453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases.
    Bosch FX; Tsu V; Vorsters A; Van Damme P; Kane MA
    Vaccine; 2012 Nov; 30 Suppl 5():F1-11. PubMed ID: 23199951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries.
    Steben M; Jeronimo J; Wittet S; Lamontagne DS; Ogilvie G; Jensen C; Smith J; Franceschi S
    Vaccine; 2012 Nov; 30 Suppl 5():F183-91. PubMed ID: 23199962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barriers to human papillomavirus vaccine acceptability in Israel.
    Fisher WA; Laniado H; Shoval H; Hakim M; Bornstein J
    Vaccine; 2013 Nov; 31 Suppl 8():I53-7. PubMed ID: 24229720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction of human papillomavirus vaccination in Nordic countries.
    Sander BB; Rebolj M; Valentiner-Branth P; Lynge E
    Vaccine; 2012 Feb; 30(8):1425-33. PubMed ID: 22154773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
    Dunne EF; Datta SD; E Markowitz L
    Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine.
    Kane MA
    Gynecol Oncol; 2010 May; 117(2 Suppl):S32-5. PubMed ID: 20129654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early policy responses to the human papillomavirus vaccine in the United States, 2006-2010.
    Laugesen MJ; Mistry R; Carameli KA; Ribisl KM; Needleman J; Bastani R
    J Adolesc Health; 2014 Nov; 55(5):659-64. PubMed ID: 24928803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
    Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
    PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.